South Africa is one of only six countries to ever meet their “fair share target” for funding tuberculosis (TB) research, according to a new report. In absolute terms however, South Africa’s contribution is small change compared to investments into TB research made by the top two contributors, the United States government and the Bill and Melinda Gates Foundation. Catherine Tomlinson unpacks what the report tells us about investment in TB research in South Africa.
On September 22 ministers, heads of state, and other officials from around the world will gather in New York for the second United Nations High-Level Meeting on TB. Yet, a few months ago it was not the governments these officials represent, but two philanthropies that stepped in to ensure arguably the most important TB trial of the decade has the funding needed to proceed. Marcus Low contrasts commitments made at the previous UN High-Level Meeting on TB with recent data on funding for TB research and asks what this tells us about the state of the global response to an age-old killer.
While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.